RMD•benzinga•
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast
Summary
ResMed posted Q3 EPS of $2.37 on $1.29 billion in sales, citing strong global demand for sleep devices, plus a boost from tariff exemptions.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 24, 2025 by benzinga